News & Updates
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, announced today the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a novel SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The highly…Read More
Excerpt from the Article: In June, MassBio released its State of Possible 2025 report, a five-year strategic plan for Massachusetts and MassBio to ensure the life sciences cluster’s long-term success. To learn more about how this report will serve as a roadmap for the next five years and beyond, we sat down with MassBio’s new…Read More
Excerpt from the announcement: Health and life sciences companies in Atlantic Canada are being invited to present their innovative solutions for improving mental health and wellness of Nova Scotians during the second Health Challenge Pitch Event. Participants will vie for a $100,000 prize and an opportunity to launch their product in collaboration with Nova Scotia…Read More
With many of our industry meetings either canceled or going virtual, we were really missing out on the casual networking we used to do at this events. If we were missing, it we thought many of you were too. So we decided to create an ongoing virtual networking series called Ask Us Anything In Clinical…Read More
Christopher Kata and the TrialStat team are exhibiting virtually at this years SCDM meeting on September 13th through the 16th. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting. You can also catch our video Pitch Presentation, and Product Showcase, or visit our Virtual Booth to learn…Read More
Excerpt from the Press Release: NEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed open-label Phase 2 study of seladelpar in patients with…Read More
Excerpt from the Press Release: SAN FRANCISCO & NEW YORK & MELBOURNE, Australia–(BUSINESS WIRE)–Synchron, a neurovascular bioelectronics medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for Stentrode, a fully-implantable medical device that can translate brain activity or stimulate the nervous system from the inside of a…Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced that it is filing an investigational new drug application (IND) for COVI-GUARD (STI-1499) for hospitalized COVID-19 patients today. Sorrento has previously received guidance from the FDA in response to a pre-IND meeting package and believes…Read More
Excerpt from the Press Release: NEWTON, Mass., Aug. 21, 2020 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham, PhD, MBA, for being selected as a finalist in the EY Entrepreneur of the Year 2020 New England Awards Program. For more…Read More
Excerpt from the article: The coronavirus has hit Black communities across the U.S. so hard that the numbers have stopped doctors in their tracks. In Philadelphia, where 42% of the population is Black and 41% is white, Black people are nearly three times more likely than white people to have the coronavirus. An appalling 52% of COVID-19 deaths in…Read More
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?